Group of Dutch Doctors & Advocates Stand up Against Leadiant Biosciences’ 500 Times Drug Price Rise

 Group of Dutch Doctors & Advocates Stand up Against Leadiant Biosciences’ 500 Times Drug Price Rise

Group of Dutch Doctors & Advocates Stand up Against Leadiant Biosciences’ 500 Times Drug Price Rise

Shots:
  • Italian pharmaceutical company, Leadiant Biosciences have gradually increased price of CDCA (chenodeoxycholic acid) from €300 year to more than €150,000, with EU’s approval in 2017 for the treatment of CTX (cerebrotendinous xanthomatosis)
  • Doctors treating CTX patients at Amsterdam Medical Center are now developing a low-priced drug against Leadiant’s CDCA.
  • Dutch health insurers have extended the support to Amsterdam Medical Center’s Doctors, which are temporarily funding Leadiant’s CDCA in the absence of low-priced substitute

Click here to read full press release/ article | Ref: Financial Times | Image:  Nomen Italia

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post